Please login to the form below

Not currently logged in
Email:
Password:

AD04

This page shows the latest AD04 news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer’s failure as Targacept trial disappoints

Another Alzheimer’s failure as Targacept trial disappoints

This June the UK's Medical Research Council (MRC) launched a £16m dementia research programme and Austrian biopharma company AFFiRiS claimed its drug candidate AD04 was the first therapy to show

Latest news

  • Burden of proof Burden of proof

    Burden of proof. Breakthroughs in Alzheimer's are sorely needed, but there's still lots of work to do on AD04. ... So a wait-and-see approach remains prudent - only further, rigorous testing will tell if AD04 really is a breakthrough.

  • AFFiRiS claims a first in Alzheimer's disease therapy AFFiRiS claims a first in Alzheimer's disease therapy

    AFFiRiS claims a first in Alzheimer's disease therapy. Says AD04 is first drug to demonstrate disease modification. ... AD02 will now take a back seat while the company places more emphasis on AD04's development.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics